Search

Pierre Beaurang Phones & Addresses

  • 1104 Sir Francis Drake Blvd, San Anselmo, CA 94960 (415) 747-1853
  • Petaluma, CA
  • 20 Wolfe Grade, Greenbrae, CA 94904 (415) 461-3601
  • 653 Via Casitas, Greenbrae, CA 94904 (415) 461-3601
  • Kentfield, CA
  • 833 Ashbury St, San Francisco, CA 94117 (415) 759-8130
  • Berkeley, CA
  • 45 Corte Real APT 8, Greenbrae, CA 94904 (415) 461-3601

Education

Degree: Graduate or professional degree

Resumes

Resumes

Pierre Beaurang Photo 1

Pierre Beaurang

View page
Location:
San Francisco Bay Area
Industry:
Biotechnology
Pierre Beaurang Photo 2

Director At Fiveprime

View page
Position:
Director at FivePrime
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
FivePrime
Director
Pierre Beaurang Photo 3

Pierre Beaurang

View page
Location:
San Francisco Bay Area
Industry:
Biotechnology
Pierre Beaurang Photo 4

Pierre Beaurang

View page
Location:
San Francisco Bay Area
Industry:
Biotechnology

Publications

Us Patents

Pharmaceutical Compositions Containing Antagonists To Lrp4, Lrp8 Or Megalin For Treatment Of Diseases

View page
US Patent:
20080254033, Oct 16, 2008
Filed:
Jan 21, 2005
Appl. No.:
10/586669
Inventors:
Kristen Pierce - Burlingame CA, US
Amy L.Tsui Collins - Oakland CA, US
Hongbing Zhang - Albany CA, US
Lewis Thomas Williams - Mill Valley CA, US
Pierre Alvaro Beaurang - Greenbrae CA, US
International Classification:
A61K 39/395
A61P 25/28
C07K 14/435
C12N 15/85
C07K 16/00
C12N 5/10
C12N 15/12
A61K 31/7105
US Classification:
4241391, 530324, 530326, 5303879, 536 235, 435325
Abstract:
The present invention provides LRP4, LRP8 and LRP2 (megalin) polypeptides; polynucleotides encoding such; modulators of LRP4, LRP8 and LRP2 activity; and pharmaceutical compositions for the treatment of diseases. Compositions of the invention contain a pharmaceutically acceptable carrier or excipient and at least one modulator that is capable of binding to or interfering with the activity of LRP4, LRP8, LRP2 and active fragments thereof. The invention provides modulators, such as antibodies, RNAi molecules, anti-sense molecules and ribozymes. Additionally, the invention includes methods for the treatment of diseases, such as proliferative diseases and degenerative diseases, and methods of administration of the compositions of the invention.

Method Of Producing Autologous Embryonic Stem Cells

View page
US Patent:
20080112937, May 15, 2008
Filed:
Jul 19, 2005
Appl. No.:
11/632860
Inventors:
Lewis T Williams - San Francisco CA, US
Hongbing Zhang - San Francisco CA, US
Srinivas Kothakota - San Francisco CA, US
Kristen Pierce - San Francisco CA, US
Pierre Alvaro Beaurang - San Francisco CA, US
Keting Chu - Hills Borough CA, US
International Classification:
A61K 48/00
C12N 5/08
C12N 15/09
US Classification:
424 9321, 435455, 435325, 435366, 435368, 435372
Abstract:
Aspects of the present invention relate to compositions and methods of reprogramming a somatic cell to give rise to an autologous embryonic stem cell. These methods involve providing a somatic cell of a donor subject, introducing the somatic cell into an embryo of a recipient subject to produce a chimeric embryo, allowing the chimeric embryo to develop further wherein the somatic cell will reprogram, and then selecting an autologous embryonic stem cell that has developed from the somatic cell. The methods and composition of producing pluripotent embryonic stem cells from a donor's own somatic cells invite the possibility of a number of therapeutic applications, including organ transplant and treatment of autoimmune diseases, cancer, and degenerative disorders such as diabetes, Alzheimer's, and Parkinson's.
Pierre A Beaurang from San Anselmo, CA, age ~54 Get Report